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Serotypes of respiratory tract isolates of Streptococcus 
pneumoniae from Jamaican children 
Upton D. Allen, (l) Sonia Thomas,c2) Jonathan Carapetis,(1,3) Sonia Henry,c2) Samia Wasfy,@) 
Marguerite Lovgren, c4) Susan Richardson@) and Donald E. Low@) 
Background: Data are lacking on the pneumococcal serotypes present in many developing regions, including the 
Caribbean. We examined the serotypes of nasopharyngeal (NP) isolates of pneumococci obtained from Jamaican 
children. 
Methods: We obtained NP samples from children seen in the Emergency Department at the Bustamante Children’s 
Hospital. The samples were transported to Canada for isolation and serotyping of pneumococci. 
Results: We obtained 94 isolates from 276 children; median age 3.4 years.The majority (57%) had symptoms of acute 
respiratory infection at the time of sampling. The main serotypes carried were 6B (20.5%), 19F (14.5%), and 14 
(8.4%). Non-typable isolates accounted for 10.8% of the isolates. Fifty-nine per cent of the serotypes were present 
among the 11 being considered for candidate pneumococcal conjugate vaccines (95% CI 48-70%); the corresponding 
proportion present in the recently licensed 7-valent vaccine was 57% (95% CI 45-67%).A significant proportion of 
the serotypes found is absent from those to be included in future conjugate vaccines (P<O.OOOl; reference=85% 
expected serotype representation). Less than 5% of isolates were non-susceptible to penicillin (3.2%), 
cefotaxime-ceftriaxone (3.2%) and cefuroxime (3.2%), while 8.4% and 1.1% of isolates were resistant to 
trimethoprim-sulfamethoxazole and erythromycin respectively. There were three isolates with resistance to two or 
more classes of drug. These isolates were all resistant to penicillin (MIC 2 ,ug/mL); the serotypes were 14,23F, and 
19F. 
Conclusion: A significant proportion of the serotypes found is absent from those to be included in future conjugate 
vaccines. 
Int J Infect Dis 2003; 7: 29-34 
INTRODUCTION 
Diseases due to Streptococcus pneumoniae (pneumo- 
cocci) are of significant public health concern globally.’ 
Each year, more than one million children less than 
5 years of age die of pneumococcal diseases, and most 
of these deaths are in developing countries1 Among 
countries where the majority of the inhabitants are of 
African ancestry, the problem posed by S. pneumoniae 
is even greater, due to the relatively high prevalence of 
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sickle-cell disease, a condition associated with significant 
morbidity and mortality from pnemocococcal sepsis.2 
It has been determined that the acquisition and 
carriage of S. pneumoniae are associated with the 
occurrence of acute otitis media,3-5 bacteremiaP8 and 
pneumonia> Knowledge of the prevalent serotypes and 
their association with antibiotic resistance is important 
for devising strategies to prevent and treat pneumo- 
coccal infections. In this context, the concern regarding 
drug-resistant S. pneumoniae has highlighted the im- 
portance of pneumococcal vaccination.‘” However, for 
many developing countries, data are lacking on the 
serotypes associated with infection in young children. 
Although sterile site isolates of S. pneumoniae provide 
a better means of evaluating disease-causing serotypes 
present in these countries, obtaining such isolates is 
often difficult. Evaluation of the serotypes associated 
with nasopharyngeal colonization provides some insight 
into the circulating serotypes, including those associated 
with antibiotic resistance.‘” 
In the above context, the objectives of this study 
were to evaluate the distribution of serotypes associated 
with nasopharyngeal colonization among a population 
of Jamaican children, and to document the prevalence of 
drug resistance among the serotypes obtained. 
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METHODS 
Setting 
The study was conducted at the Emergency Depart- 
ment of the Bustamante Children’s Hospital, Kingston, 
Jamaica. This is the largest pediatric hospital in the 
English-speaking Caribbean. It is located in the nation’s 
capital, Kingston, which has a population of over 
250 000 people. The total population of Jamaica is 
approximately 2.2 million; the majority are of African 
descent. The patient population consists primarily of 
children less than 10 years of age who predominantly 
belong to a lower socioeconomic group. The vast 
majority of the children seen are from inner city urban 
areas. 
Design and eligibility criteria 
This was a point prevalence study that targeted all 
children presenting to the Emergency Department over 
a 5-day period in June 1999. Following verbal informed 
consent, a short questionnaire was administered to 
the accompanying caregiver. The information obtained 
included demographic data, reason(s) for the visit to 
hospital, underlying diseases, and current or recent anti- 
biotic use. 
Sample collection and laboratory processing 
A sterile Dacron polyester-tipped swab (Hardwood Pro- 
ducts Company, Guilford, ME, USA) was used to obtain 
a nasopharyngeal sample from each child. The swabs 
were taken by one of two physicians, immediately placed 
into skim milk-glucose-glycerol broth,*l and frozen 
within l-2 h at approximately -1O’C.). The samples 
were taken to Toronto on dry ice and kept frozen at 
-70°C prior to laboratory processing. S. pneumoniae 
was isolated using standard laboratory techniques.i* 
Samples were plated onto 5% sheep blood agar, and 
incubated in CO2 at 35°C for 18-24 h. S. pneumoniae 
was identified by a-hemolysis, colony morphology, 
optochin susceptibility, and bile solubility.l* In selecting 
colonies of pneumococci, three to five colonies were 
picked up for identification. 
Susceptibility testing was performed by broth 
microdilution according to guidelines provided by the 
National Committee for Clinical Laboratory Standards 
(NCCLS), and interpretation was based on NCCLS 
breakpoints (1999). 13,14 In this regard, the breakpoints 
and interpretative standards for penicillin were as follows: 
~0.06 yg/mL=sensitive; 0.12-l yg/mL=intermediate; 
and ~2 yg/mL=resistant (non-susceptible=inter- 
mediate or resistant; susceptible=sensitive). In addition 
to penicillin, other antimicrobials tested included 
cefotaxime-ceftriaxone, erythromycin, doxycycline, 
trimethoprim-sulfamethoxazole, and chloramphenicol. 
Serotyping based on the Quellung reaction15 using com- 
mercial antisera obtained from the Statens Seruminstitut, 
Copenhagen, Denmark was performed at the National 
Centre for Streptococcus, Edmonton, Canada. 
Statistical analyses 
Data management was facilitated by Epi Info softwarer6 
using descriptive analyses. The one-sample test of 
binomial proportions was used to determine confidence 
intervals around point estimates and to compare the 
serotypes present among the study population with those 
covered by current pneumococcal conjugate vaccines. 
RESULTS 
Nasopharyngeal isolates were obtained from 276 children 
with a median age of 3.4 years (range 0.1-17.7 years). 
The male/female ratio was l.l:l. Symptoms of acute 
respiratory tract infection were present in 57.4% of the 
subjects. Among 274 subjects with adequate informa- 
tion, 24.8% indicated that they had received antibiotics 
in the previous month. The single most frequent reason 
for the hospital visit was hyperreactive airway disease 
(14.3% of subjects). Less than 0.5% (l/276) had overt 
evidence of malnutrition, while 0.7% (2/276) had sickle- 
cell disease. 
Ninety-four isolates of S. pneumoniae were obtained 
from the 276 children (34% carriage). These 94 isolates 
were from 93 different children. Eighty-three isolates 
were viable for serotyping. The relative frequencies of 
the most common serotypes were: 6B,20.5%; 19F, 14.5%; 
14,8.4%; 23F, 7.2%; 6A, 7.2%; 16F,4.8%; and 19A, 4.8%. 
One subject carried two serotypes (19F and non-typable). 
Figure 1 shows the distribution of the various serotypes, 
including 10.8% of the isolates that were non-typable. 
We examined the proportion of the isolates repre- 
sented in candidate 7- and 11-valent conjugate vaccines. 
Fifty-nine per cent of the serotypes were present among 
the 11 being considered for candidate pneumococcal 
conjugate vaccines (95% CI 48-70%). The proportion 
covered by the recently licensed 7-valent vaccine was 
57% (95% CI 45-67%). A significant proportion of the 
serotypes found is absent from those to be included 
in future conjugate vaccines (P<O.OOOl; reference=85% 
expected serotype representation). 
Susceptibility testing was performed on 94 isolates. 
Less than 5% of isolates were non-susceptible to peni- 
cillin (3.2%), cefotaxime-ceftriaxone, and cefuroxime 
(3.2%), while 8.4% of isolates were resistant to 
trimethoprim-sulfamethoxazole. Erythromycin resist- 
ance was low (1.1%). No isolates were resistant to 
doxycycline, while 2.1% were resistant to chloram- 
phenicol. Three isolates showed resistance to two or 
more classes of drug. The penicillin minimum inhibitory 
concentration for each of these three isolates was 
2 ug/mL).The serotypes of the above three isolates were 
14, 23F, and 19F, respectively. While the numbers of 
resistant isolates were low, there was no indication that 
Serotypes of respiratory tract isolates of Streptococcus pneumoniae from Jamaican children I Allen et al 31 
6B 19F NT 14 23F 6A 19A 16F 13 11A 9V 3 18C 4 7C IOA 15B 18B 34 38 
Serotypes 
Figure 1. Serotypes of nasopharyngeal isolates of pneumococci-Jamaican children, 1999. Serotypes contained in the 7-and 11-valent 
conjugate vaccines are indicated by an arrow. NT denotes non-typable isolates. 
current or recent antibiotic use was associated with 
carriage of such resistant isolates. 
DISCUSSION 
Invasive pneumococcal infections in North American 
children are most often caused by serotypes 4,6B, 9V, 14, 
18C, 19F, and 23F.i’ Serotypes 6B, 9V, 14,19A, 19F and 
23F are the isolates that are most frequently associated 
with resistance to penicillin.*8.19 Our results provide 
data on the serotypes associated with nasopharyngeal 
carriage in a group of Caribbean children. The main 
isolates were virtually identical to those identified in 
a similar study involving children attending pediatric 
practices in the private sector in Johannesburg,2” where 
the predominant serotypes were 6B, 19F, 6A, 23F, 14, and 
19A, compared with 6B, 19F, 14,23F, 6A, 16F and 19A 
in the Caribbean study. 
The serotypes present in 7-valent vaccines include 
4, 6B, 9V, 14, 18C, 19F, and 23E21 The 11-valent 
formulation also includes types 1, 3,.5, and 7F.22 In the 
developed countries, an 11-valent pneumococcal con- 
jugate vaccine is expected to cover up to 85% of invasive 
isolates in young children. 22 While many of the sero- 
types that were identified in our study are included 
in candidate pneumococcal vaccines, a significant 
proportion is absent. This concurs with studies from 
other regions of the developing world, where in some 
cases less than two-thirds of carriage isolates belong to 
the serotypes included in current 7-valent or 9-valent 
vaccines.23.24 The relevance of this would depend on the 
extent to which the isolates that we identified were 
associated with antibiotic resistance or diseases such as 
otitis media, meningitis, pneumonia, and bacteremia. 
In the above context, with respect to the serotypes 
associated with specific diseases, additional studies are 
needed to address this issue in many developing regions 
of the world. Notwithstanding this, it has been shown 
that the vast majority of children with acute lower 
respiratory tract infection and pneumococcal bacteremia 
carry the same pneumococcal serotypes in their 
oropharynx.2s Dagan and others have determined that, 
at least for acute otitis media, carriage of resistant S. 
pneumoniae in the community correlates with disease 
caused by the resistant strains.‘” With the exception of 
non-typable isolates, it is likely that the serotypes 
identified in our study reflect a significant proportion of 
those associated with pneumococcal disease. 
With respect to the serotypes associated with 
resistance in the population studied, our study provides 
important preliminary data. The level of penicillin non- 
susceptibility among the serotypes was less than 5%. In 
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addition, the level of macrolide resistance was low. In 
1993-94 (November to March), we conducted a survey 
in the same target population at the same institution, 
and found that the level of penicillin resistance was less 
than 5%.26 However, in 1995 (summer) we observed 
that the level of resistance was just under 20%. In the 
1993-94 and 1995 surveys, no macrolide-resistant isolates 
were observed. Seasonal differences in the proportion of 
resistant isolates would not explain these results, as the 
1995 and 1999 isolates were collected during identical 
seasons (summer months). With respect to the level of 
resistance detected in 1995, we postulate that there may 
have been circulating clones of specific serotypes 
associated with resistance. In the current survey, 
we found that the multiresistant isolates belonged to 
serotypes 14, 23F, and 19F. This is consistent with the 
serotypes that are known to be most frequently associa- 
ted with resistance.‘s,19 
Overall, the level of pneumococcal antibiotic 
resistance is at the lower end of the range of prevalence 
documented worldwide.27-31 With respect to developing 
countries in the region of the Americas, Kertesz et al 
obtained invasive pneumococcal isolates from six Latin 
American countries (Argentina, Brazil, Chile, Columbia, 
Mexico, and Uruguay). 28 Overall, 25% of isolates had 
diminished susceptibility to penicillin, with 8.3% show- 
ing high-level resistance. While it is well established that 
prior antibiotic use selects for carriage of resistant 
strains of S. pneumoniae,31A3 it is unclear whether the 
level of resistance observed in our study is due to less 
antibiotic pressure in the study population compared 
with other regions. Over-the-counter antibiotics are not 
available in Jamaica. It is also possible that Jamaica may 
not yet have some of the major resistant clones that 
have become prevalent in some countries. 
The pneumococcal conjugate vaccine, like the 
Haemophilus injiuenzae-type b conjugate vaccine, has 
been shown to decrease carriage of specific serotypes in 
the vaccine, including resistant serotypes.41 Consequently, 
a vaccine that is effective against the limited number 
of serotypes associated with antibiotic resistance may 
decrease the prevalence of infections caused by anti- 
biotic-resistant pneumococci. It is tempting to speculate 
that, at this time, there is a window of maximum benefit 
to be derived from the use of the conjugate vaccine in 
regions that currently have a low level of antibiotic 
resistance. In this way, the goal would be to see the 
conjugate vaccine as an important component of a 
strategy to limit the emergence and spread of antibiotic 
resistance; a strategy that would include measures to 
promote judicious antibiotic use. However, it should be 
noted that there are data showing that the reduction in 
number of serotypes following the use of the conjugate 
vaccine may be followed by replacement with other 
serotypes not included in the vaccine.42 It is unknown 
whether the latter serotypes will become the ones 
predominantly responsible for disease and resistance in 
the future.‘O 
We acknowledge the fact that the data presented in 
this study were collected over a relatively short period 
of time. However, the data are preliminary, and 
represent the only such data available from the target 
population at this point in time. Additional data will be 
obtained from a wider cross-section of children. Such 
data will include isolates obtained from sterile sites. 
Our data support the need for the further develop- 
ment of pneumococcal vaccination, including pneumo- 
coccal protein vaccines. Proteins that are virulence 
factors for pneumococci have been identified. These 
include pneumococcal surface protein A (PspA), 
pneumococcal surface adhesion A protein (PsaA), and 
pneumolysin. 44,45 These proteins are being evaluated in 
experimental models singly and in combination.44,45 It 
is possible that, in the future, the inclusion of these 
proteins in polysaccharide-protein conjugate vaccines 
will result in enhanced efficacy of the vaccines against 
pneumococcal disease and offer coverage against sero- 
types that are not included in the current pneumococcal 
vaccines. 
In summary, we have generated baseline data on the 
circulating serotypes that are carried, including those 
that are associated with antibiotic resistance in a popu- 
lation of Jamaican children before the advent of the 
conjugate pneumococcal vaccine in that region. The 
occurrence of antibiotic-resistant serotypes in this study 
sample is relatively low. There is a significant proportion 
of serotypes present that are not included in current 
candidate pneumococcal conjugate vaccines. However, 
if the isolates identified are in concordance with disease- 
causing strains, the data suggest that the current 7-valent 
vaccine would provide similar coverage to an 11-valent 
formation. 
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